REG - Hemogenyx Pharma Plc - Grant of Options and Extension of Warrant Term

Hemogenyx PharmaceuticalsAnnouncement

29/05/2026 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260529:nRSc2356Ga&default-theme=true

RNS Number : 2356G  Hemogenyx Pharmaceuticals PLC  29 May 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

29 May 2026

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Grant of Options and Extension of Warrant Term

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical
group focused on developing treatments for cancers and viral diseases,
announces the grant of share options and a variation to the exercise period
for certain investor warrants.

Grant of Share Options

The Board of Directors has agreed to grant options over a total of 1,200,000
ordinary shares of 1p each in the capital of the Company ("Board Share
Options") to the Company's Non-Executive Directors Peter Redmond, Alexis
Sandler, Sir Marc Feldmann (Chairman) and Executive Director Vladislav Sandler
(CEO).

The details of the Board Share Options granted are set out below:

 Name               Position                Number of Share Options Granted  Exercise Price (pounds)  Expiry Date
 Peter Redmond      Non-executive Director  300,000                          8.0                      29 May 2031
 Sir Marc Feldmann  Non-executive Chairman  300,000                          8.0                      29 May 2031
 Vladislav Sandler  CEO                     300,000                          8.0                      29 May 2031
 Alexis Sandler     Non-executive Director  300,000                          8.0                      29 May 2031
 Koen Van Besien    Medical Director        60,000                           8.0                      29 May 2031

Further, options have been granted to employees over a total of 60,000
ordinary shares of 1p each in the capital of the Company ("Employee Share
Options").  The Employee Share Options will have an exercise price of £8 and
expire on 29 May 2031.

The Board and Employee Share Options will vest immediately.

Following the grant of the Board and Employee Share Options there are, in
aggregate, 1,410,479 ordinary shares of 1p each in the Company under option
held by directors, employees and members of the Scientific Advisory Board of
the Company, representing 20.7% of the issued ordinary share capital of the
Company.

Extension to warrant exercise period

The Company has extended the term of 69,048 warrants granted to a group of
investors to 7 September 2026 (the "Warrants"). The Warrants were originally
granted to the investors on 8 March 2025 with a term of fifteen months.

The Board has concluded that the term of the Warrants should be extended to be
aligned with the terms of other existing warrants. All other terms of the
Warrants remain unchanged including the exercise price.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 AlbR Capital Limited                                            Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZGZKRLVGVZG



            Copyright 2019 Regulatory News Service, all rights reserved